Blogs

Latest Blogs

[wd_asp id=2]

Antibody‑Drug Conjugates (ADCs): The Tipping Point

The field of antibody-drug conjugates (ADCs) is entering an exciting era, and there is no shortage of writing today about where this modality is headed:…

Where Does Bioanalysis Fit into Drug Discovery Pipelines?

Bioanalysis is foundational for investigational therapeutic agents. This blog post will define the bioanalysis of molecules and highlight its beneficial…

EBF OS 2025: My Key Highlights

A unifying message across EBF 2025 was that bioanalytical science is transitioning from technical execution to decision support. For years,…

S-Pindolol: Combatting Cancer Cachexia Effectively

Cancer cachexia is a silent thief. It robs patients of strength, stripping away muscle and fat, leaving them frail and…

The Silence of the Genes: Unlocking Antisense Oligonucleotide Therapies for the Renin-Angiotensin-Aldosterone System

The field of gene therapy is rapidly evolving, with antisense oligonucleotide therapies emerging as powerful tools for modulating gene expression.…

From Signals to Systems: Olink Proteomics as a Cornerstone of Synexa’s Biomarker Strategy

We have entered a new era of modern science, where therapeutic innovation is reshaping the field of medicine.…

GMP Grade Ligand Binding and Potency Assays – Frequently Asked Questions

Good Manufacturing Practice ligand binding and potency assays are essential for ensuring the quality, safety, and regulatory compliance of biopharmaceutical…

Talk to our Biomarker Experts